@article {P{\'e}rez de LlanoP3476, author = {Luis P{\'e}rez de Llano and Jos{\'e} Manuel Zubeldia and Lys Herr{\'a}ez}, title = {Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study}, volume = {44}, number = {Suppl 58}, elocation-id = {P3476}, year = {2014}, publisher = {European Respiratory Society}, abstract = {Background: Significant clinical experience has been gained after five years from the approval of omalizumab in Spain.Objective: To describe patterns of use of omalizumab in current clinical practice in Spain.Methods: Retrospective, multicenter, study based on medical records from patients treated with omalizumab between Jan-2006 and Sep-2011.Results: 464 patients (63.8\% female, mean age 45.6{\textpm}19.3 years) were included. Omalizumab was mainly prescribed for the treatment of asthma (84.5\%), followed by chronic urticaria (5.6\%), food allergy (5.2\%), atopic dermatitis (2.4\%) and allergic bronchopulmonary aspergillosis (1.7\%). The disease was severe in 76.7\% of cases. During the year before omalizumab was started, asthma patients required an average of 2.7{\textpm}3.7 emergency visits and 0.4{\textpm}1.2 hospital admissions with a mean stay of 10.8{\textpm}11.2 days. Mean number of unscheduled primary and specialized care visits were 3.5{\textpm}3.9 and 1.8{\textpm}2.3 respectively. The average lost working days was 7.9{\textpm}22.3. The main reasons to start omalizumab treatment were the lack of efficacy with conventional (93.1\%) or alternative therapy (22.0\%), and the appearance of adverse events with other drugs (18.5\%). Modifications of omalizumab dosage/frequency were detected in 17.5\% of cases. Overall efficacy of omalizumab was rated as good/excellent in 64.4\%. Efficacy was evaluated on the basis of clinical improvement (87.7\%), disease control (77.6\%), reduction of exacerbations (72.2\%) and quality of life (33.4\%).Conclusions: Severe asthma was the main indication for omalizumab prescription, albeit other serious and long-standing immunological diseases were identified. Omalizumab is a good therapeutic option for all the evaluated indications.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/44/Suppl_58/P3476}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }